H1N1 Influenza
13
0
0
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
23.1%
3 terminated out of 13 trials
66.7%
-19.8% vs benchmark
15%
2 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome
Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml
ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS
Comparison of COVID-19 and H1N1 Influenza Pneumonia
Tomographic Findings in COVID-19 and Influenza
STIP: Statin Trial for Influenza Patients
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV
Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial
Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza
H1N1 Vaccine Safety in Manitoba, Canada
The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A
Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation